Jim Cramer’s Recent Responses to Questions About 12 Stocks

7. Jacobs Solutions Inc. (NYSE:J)

Number of Hedge Fund Holders: 35

Jacobs Solutions Inc. (NYSE:J) is one of the stocks Jim Cramer recently answered questions about. Responding to a caller’s question about the stock during the lightning round, Cramer said:

“Okay, let me just say right now, Jacobs Solutions, I think, was incorrectly valued last week when an analyst came out and said that they did not do the number and did not do the forecast. That was not true. Bob Pragada did the number, and he gave a good forecast. And that’s why I think that Goldman Sachs recommended it today. I can’t speak highly enough about both Jacobs and the price that it’s at. I would buy this thing at $132.”

Jacobs Solutions Inc. (NYSE:J) provides consulting, design, engineering, and infrastructure delivery services for several industries. Cramer highlighted the company’s data center business during the October 7 episode, as he commented:

“I want to highlight another group that doesn’t get as much attention, actually, kind of gets almost no attention despite the fact that they’re some of the clearest winners in this whole process. I’m talking about what we used to call the ENC stocks, the engineering construction firms that literally build the data centers. Take Jacobs Solution, up almost 48% from its April lows… Jacobs has been in the data center construction business since 2007… The digital twin concept is a real cost-saver, especially in times of tremendous materials inflation.

And look, the data center exposure is already paying off. When Jacobs reported its most recent quarter, the company delivered a nice earnings boost and raised its full-year earnings forecast. Nice, huh? Management called out the data center boom as one of the top drivers of the company’s core infrastructure and advanced facilities business. Look, I think Jacobs remains a winner both for the data center and because they can make a bundle from new manufacturing facilities being built in the United States, including pharmaceutical plants. Think of them as a terrific reshoring play.”